OTCMKTS:BIOVF Q2 EPS Forecast Decreased by HC Wainwright

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) – Equities researchers at HC Wainwright lowered their Q2 2027 earnings estimates for shares of Swedish Orphan Biovitrum in a research note issued to investors on Friday, September 11th. HC Wainwright analyst M. Kapoor now anticipates that the company will post earnings per share of $0.67 for the quarter, down from their previous forecast of $0.68. The consensus estimate for Swedish Orphan Biovitrum’s current full-year earnings is $1.91 per share.

A number of other equities analysts also recently weighed in on BIOVF. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of Swedish Orphan Biovitrum in a report on Tuesday, July 21st. Pareto Securities downgraded Swedish Orphan Biovitrum to a “hold” rating in a research note on Monday, June 29th. Finally, Barclays reiterated an “overweight” rating on shares of Swedish Orphan Biovitrum in a research report on Friday, July 3rd. Four investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy”.

Swedish Orphan Biovitrum Price Performance

BIOVF stock opened at $48.13 on Thursday. The stock has a market cap of $17.13 billion, a P/E ratio of 106.95 and a beta of 0.33. The company has a current ratio of 0.88, a quick ratio of 0.55 and a debt-to-equity ratio of 0.20. The stock’s fifty day simple moving average is $48.39 and its two-hundred day simple moving average is $45.71. Swedish Orphan Biovitrum has a 1-year low of $29.18 and a 1-year high of $49.03.

About Swedish Orphan Biovitrum

Swedish Orphan Biovitrum AB, commonly known as Sobi, is a Swedish biopharmaceutical company focused on developing, manufacturing and commercializing therapies for rare diseases. Its principal areas of activity include hematology, immunology and specialty care, with an emphasis on conditions that have limited treatment options and relatively small patient populations.

Sobi’s portfolio includes treatments for hemophilia and other bleeding disorders, such as Elocta, Alprolix and Vonvendi, as well as medicines for immune-mediated and hematologic conditions.